Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
Pfizer Inc. (NYSE:PFE, "Pfizer")) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
"IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoing battle against infectious diseases," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. "At Pfizer, we continue to prioritize innovation and rigorous data generation through clinical studies and real-world analysis supporting the vaccines and therapeutics for our infectious disease pipeline."
Presentations will include research from Pfizer's diverse infectious disease portfolio, including COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, and other serious bacterial and viral infections. Details for the oral and poster presentations are below:
Title/Abstract Number |
Presenting Name/Type |
Date/Time (ET) |
Location |
ORAL & LATE-BREAKING PRESENTATIONS |
|||
Attitudes about COVID and Community Engagement with Patients (ACCEPt): Global Survey Reveals the Ongoing Impact of Long COVID-19 on Medically Vulnerable Populations, Five Years On |
R Paredes |
Oct 22 4:15 – 4:30PM |
B211-B212 |
Effectiveness of the JN.1-adapted BNT162b2 COVID-19 Vaccine in High-Risk Groups against Hospitalization in Europe: A Test-Negative Case-Control using the id.DRIVE Platform |
H Volkman |
Oct 21 1:45 – 3:00PM |
B401-B402 |
Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Lower Respiratory Tract Disease (LRTD) Hospitalizations and Emergency Department Admissions over Two RSV Seasons—Kaiser Permanente of Southern California (KPSC), October 2023–April 2025 |
S Tartof |
Oct 20 3:15 – 4:30PM |
B401-B402 |
Immunosuppression and RSV Prefusion F Protein Vaccine Effectiveness in Older Adults: A Prespecified sub analysis from the DAN-RSV Trial |
A Jensen |
Oct 20 3:15 – 4:30PM |
B401-B402 |
POSTER PRESENTATIONS |
|||
COVID-19 |
|||
COVID-19 vaccine uptake in children aged 1 - 4 years from state vaccine registry data through March 2024 |
T Ahi |
Oct 22 12:15 PM |
Poster Hall B4-5 |
Public Health and Economic Impact of Increased Uptake of an Additional Dose of Pfizer-BioNTech KP.2-Adapted COVID-19 Vaccine, 2024-2025 Formula, Among US Adults ≥ 65 Years of Age |
A Yehoshua |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Physician Perceptions and Decision-Making Factors in Prescribing COVID-19 Antivirals: Qualitative Research Findings |
M Fernandez |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Ibuzatrelvir Potently Reduced Viral RNA Levels Despite the High Rate of Anti-S Seropositivity: a Post Hoc Analysis of Serology in the Phase 2b Study in Adults Without Risk Factors for Severe COVID-19 |
JH Kim |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Inpatient Burden of Respiratory Syncytial Virus, COVID-19, or Influenza in the United States Among Children < 5 Years of Age |
K Andersen |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Severity of Omicron COVID-19 variants: a global systematic literature review |
D Malhotra |
Oct 22
12:15 PM |
Poster Hall B4-5 |
COVID-19 Case Attack Rate Differences by Vaccination Status and Vaccine Effectiveness among US Nursing Home Residents, October 5, 2024 to January 5, 2025 |
F Khan |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Invasive Group B Streptococcus (GBS) |
|||
Invasive Group B Streptococcus among hospitalized pregnant and postpartum women, 2016-2024: a Unites States database study |
S Willis |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Long-Term Healthcare Utilization and Expenditures for Infants with Invasive Bacterial Infections During Birth Hospitalizations |
K Schley |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Lyme Disease |
|||
Risk Perception and Communication about Lyme Disease Prevention by Healthcare providers: A Mixed-Methods Study |
N Patel |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Gestational Lyme disease incidence and pregnancy-related outcomes among women in the United States, 2015-2024 |
S Willis |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Healthcare Costs Associated With Lyme Disease Among Medicare Fee-for-Service Beneficiaries in the United States: A Retrospective Claims-Based Study |
H Yu |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Meningococcal Disease |
|||
Need for Broad Protection Against Invasive Meningococcal Disease Among US College Students |
J Presa |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Characterization of Factor H Binding Protein Expression for Neisseria meningitidis Serogroup B Isolates, 2015–2022 |
K Weiss |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Clinical Development of MenABCWY (PenbrayaTM), a Broadly Protective Pentavalent Meningococcal Vaccine |
L Zoloras |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Utility of the Pentavalent MenABCWY Meningococcal Vaccine (PenbrayaTM) Within Alternative US Meningococcal Vaccination Schedules |
J Presa |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Ten-year retrospective review of medical records at five hospitals in the United States highlights the potential for under-detection of invasive meningococcal disease |
F Angulo |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Awareness, Attitudes and Perceptions of Meningococcal Vaccines among Caregivers of Adolescents in the United States |
J Presa |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Pneumococcal Disease |
|||
Re-evaluating economic & health impact of PCV20 in adults using real-world effectiveness data |
J Vietri |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Invasive pneumococcal pneumonia: is bacteremia the appropriate indication of severity? |
P Peyrani |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Variability in Case-Ascertainment Methodology and Rates of Adult Invasive Pneumococcal Disease using a US Healthcare Claims Database |
A Miles |
Oct 22
12:15 PM |
Poster Hall B4-5 |
Temporal Trends in Rates of Hospitalized Pneumonia among US Adults and Residual Disparities by Race and Socioeconomic Status |
A Miles |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Demographic and Clinical Characteristics, by Pneumococcal Serotype, of Adults Hospitalized with Community Acquired Pneumonia in the US |
L Grant |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Differences in invasive pneumococcal disease clinical presentations and serotype distribution among children with and without underlying risk factors |
K Hulten |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Nasopharyngeal Colonization in South Texas Children Less Than 6 Years of Age With or Without Lower Respiratory Tract Infections |
K Hulten |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults 65-74, 75-84, and ≥85 years of age in the United States |
A Miles |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Uptake and Series Completion with Pneumococcal Conjugate Vaccine by Social Determinants of Health among Children in the United States |
A Miles |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Influenza |
|||
Symptom Burden During the First Week of Acute Influenza Infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study during the 2024/25 Season |
T Hu |
Oct 20
12:15 PM |
Poster Hall B4-5 |
The Burden of Influenza on Health-Related Quality of Life and Work Productivity During the First Week of infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study |
T Hu |
Oct 22
12:15 PM |
Poster Hall B4-5 |
The Socioeconomic Value of Adult Respiratory Vaccination in the United States: A Benefit-Cost Analysis |
T Hu |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Respiratory Syncytial Virus (RSV) |
|||
How do recent population-level RSVpreF vaccine impact results from the United Kingdom relate to previously reported vaccine effectiveness results? |
N Aliabadi |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Bivalent RSV Prefusion F-Based Subunit Vaccine Recipients with Chronic Kidney Disease Achieved High Neutralizing Titers One Month After Vaccination |
F Rahman |
F Oct 21
12:15 PM |
Poster Hall B4-5 |
Immunogenicity and Safety of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Non-Pregnant HIV Infected Older Adults |
T Mikati |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis |
C Liang |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Time to Testing, Diagnosis, and Hospitalization Among Pediatric and Adult Patients with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US |
W Tang |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Time-Series Model Estimation of RSV-Attributable Respiratory Hospitalizations and Mortality in Adults in Finland |
C Liang |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Burden of Hospitalizations Due to Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations |
A Tippett |
Oct 20
12:15 PM |
Poster Hall B4-5 |
What if Adult RSV Vaccine Uptake in the US was High Like in Scotland? Missed Opportunities to Reduce Public Health and Economic Burden of RSV |
R Sato |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Strategies to promote adult vaccination against respiratory pathogens: a narrative literature review |
E Williams |
Oct 21
12:15 PM |
Poster Hall B4-5 |
Attributes of Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus (RSV): Results of a Systematic Literature Review |
K Date |
Oct 20
12:15 PM |
Poster Hall B4-5 |
RSV Signs and Symptoms at Time of Hospitalization among Pediatric and Adult Population with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US |
W Tang |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Tick-Borne Encephalitis (TBE) |
|||
Tick-borne encephalitis (TBE) in international travelers and TBE vaccine recommendations for travelers to Europe |
F Angulo |
Oct 20
12:15 PM |
Poster Hall B4-5 |
Prescribing Information for Pfizer Medicines
Please see full Prescribing Information for ABRYSVO® (Respiratory Syncytial Virus Vaccine) or visit https://abrysvoadult.pfizerpro.com.
Please see full Prescribing Information for COMIRNATY® (COVID-19 Vaccine, mRNA) or visit https://comirnatyhcp.com.
Please see full Prescribing Information including BOXED WARNING for PAXLOVIDTM (Nirmatrelvir and Ritonavir) or visit https://paxlovid.pfizerpro.com.
Please see full Prescribing Information for PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine) or visit https://prevnar20.pfizerpro.com.
Please see full Prescribing Information for PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information for PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine) or visit https://penbraya.pfizerpro.com.
Please see full Prescribing Information for TRUMENBA® (Meningococcal Group B Vaccine) or visit https://trumenba.pfizerpro.com.
Please see full Prescribing Information for TICOVAC™.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of October 13, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer's infectious disease pipeline, in-line products and product candidates, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer's infectious disease products and product candidates; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer's product candidates; whether and when any such applications that may be pending or filed for any of Pfizer's product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer's products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S.; uncertainties regarding the ability to obtain or maintain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations, including uncertainties related to the potential impact of narrowing recommended patient populations; challenges related to public vaccine confidence or awareness; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013078360/en/
Media contact: [email protected]
Investor Contact: [email protected]